ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
The correlates of hyperechogenicity of the substantia nigra in subjects at risk of dementia with Lewy bodies.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substantia nigra hyperechogenicity (SN+) detected by transcranial sonography (TCS) has been proposed as a risk marker for synucleinopathies, particularly Parkinson's disease. Its role in prodromal dementia with Lewy bodies (DLB) remains insufficiently explored. To examine clinical, cognitive, genetic, EEG, and plasma biomarker differences between SN+ and normal echogenicity (SN-) individuals in a well-characterized at-risk-of-DLB cohort, with additional sex-stratified analyses. A total of 121 participants aged 55-70 years from an at-risk-of-DLB cohort underwent TCS, neurological and neuropsychological assessment, nighttime wrist actigraphy, high-density EEG, genetic testing for APOE allelic variants, and plasma biomarker analysis (NfL, GFAP, pTau181). SN status was defined using laboratory-specific cut-offs. Group differences were assessed using non-parametric statistics with relevant corrections for multiple comparisons and adjustment for age. SN+ status as compared to SN- status was associated with poorer verbal memory performance and altered visuo-constructive performance (driven mostly by males), and significant differences in distinct actigraphy-derived sleep parameters. SN+ participants showed higher plasma NfL levels (particularly in males) and a higher prevalence of DLB-specific EEG patterns (driven by females). No significant associations were observed for global cognition, motor parkinsonism, cognitive fluctuations, hallucinations, REM sleep behavior disorder, depressive symptoms, olfactory function, plasma biomarkers of degeneration, neuroinflammation, β-amyloid deposition, or APOE status. In individuals at risk of DLB, SN hyperechogenicity is linked to early markers of neurodegeneration and cholinergic dysfunction, including elevated NfL and DLB-specific EEG abnormalities, as well as selective posterior cortical cognitive impairment and sleep disturbances. The observed sex-specific effects require further investigation.
Indexed as
Identifiers
42133012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.